Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Antimicrobial Resistance & Infection Control
Published in: Antimicrobial Resistance & Infection Control 1/2017

Open Access 01-12-2017 | Research

Genome sequencing and analysis of the first spontaneous Nanosilver resistant bacterium Proteus mirabilis strain SCDR1

Authors: Amr T. M. Saeb, Khalid A. Al-Rubeaan, Mohamed Abouelhoda, Manojkumar Selvaraju, Hamsa T. Tayeb

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2017

Login to get access

Abstract

Background

P. mirabilis is a common uropathogenic bacterium that can cause major complications in patients with long-standing indwelling catheters or patients with urinary tract anomalies. In addition, P. mirabilis is a common cause of chronic osteomyelitis in Diabetic foot ulcer (DFU) patients. We isolated P. mirabilis SCDR1 from a Diabetic ulcer patient. We examined P. mirabilis SCDR1 levels of resistance against Nanosilver colloids, the commercial Nanosilver and silver containing bandages and commonly used antibiotics. We utilized next generation sequencing techniques (NGS), bioinformatics, phylogenetic analysis and pathogenomics in the characterization of the infectious pathogen.

Results

P. mirabilis SCDR1 was the first Nanosilver resistant isolate collected from a diabetic patient polyclonal infection. P. mirabilis SCDR1 showed high levels of resistance against Nanosilver colloids, Nanosilver chitosan composite and the commercially available Nanosilver and silver bandages. The P. mirabilis -SCDR1 genome size is 3,815,621 bp. with G + C content of 38.44%. P. mirabilis-SCDR1 genome contains a total of 3533 genes, 3414 coding DNA sequence genes, 11, 10, 18 rRNAs (5S, 16S, and 23S), and 76 tRNAs. Our isolate contains all the required pathogenicity and virulence factors to establish a successful infection. P. mirabilis SCDR1 isolate is a potential virulent pathogen that despite its original isolation site, the wound, can establish kidney infection and its associated complications. P. mirabilis SCDR1 contains several mechanisms for antibiotics and metals resistance, including, biofilm formation, swarming mobility, efflux systems, and enzymatic detoxification.

Conclusion

P. mirabilis SCDR1 is the first reported spontaneous Nanosilver resistant bacterial strain. P. mirabilis SCDR1 possesses several mechanisms that may lead to the observed Nanosilver resistance.
Appendix
Available only for authorised users
Literature
1.
Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett. 2008;176:1–12.CrossRefPubMed
2.
Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns J. Int. Soc. Burn Inj 2004;30 Suppl 1:S1–9.
3.
Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, et al. Silver nanoparticles as potential antibacterial agents. Mol. Basel Switz. 2015;20:8856–74.
4.
Lu L, Sun RW-Y, Chen R, Hui C-K, Ho C-M, Luk JM, et al. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther. 2008;13:253–62.PubMed
5.
6.
Oyanedel-Craver VA, Smith JA. Sustainable colloidal-silver-impregnated ceramic filter for point-of-use water treatment. Environ Sci Technol. 2008;42:927–33.CrossRefPubMed
7.
Prabhu S, Poulose EK. Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. Int. Nano Lett. 2012;2:32.CrossRef
8.
Samuel U, Guggenbichler JP. Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. Int J Antimicrob Agents. 2004;23(Suppl 1):S75–8.CrossRefPubMed
9.
Saeb ATM, Alshammari AS, Al-Brahim H, Al-Rubeaan KA. Production of silver nanoparticles with strong and stable antimicrobial activity against highly pathogenic and multidrug resistant bacteria. ScientificWorldJournal. 2014;2014:704708.CrossRefPubMedPubMedCentral
10.
Velázquez-Velázquez JL, Santos-Flores A, Araujo-Meléndez J, Sánchez-Sánchez R, Velasquillo C, González C, et al. Anti-biofilm and cytotoxicity activity of impregnated dressings with silver nanoparticles. Mater Sci Eng C Mater Biol Appl. 2015;49:604–11.CrossRefPubMed
11.
Lullove EJ, Bernstein B. Use of SilvrSTAT® in lower extremity wounds: a two center case series « Journal of Diabetic Foot Complications 2015;7:13–16.
12.
Hendry AT, Stewart IO. Silver-resistant Enterobacteriaceae from hospital patients. Can J Microbiol. 1979;25:915–21.CrossRefPubMed
13.
McHugh GL, Moellering RC, Hopkins CC, Swartz MN. Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet Lond Engl. 1975;1:235–40.CrossRef
14.
Gunawan C, Teoh WY, Marquis CP. Amal R. Induced adaptation of Bacillus sp to antimicrobial nanosilver Small Weinh Bergstr Ger. 2013;9:3554–60.
15.
Jansen AM, Lockatell CV, Johnson DE, Mobley HLT. Visualization of Proteus Mirabilis morphotypes in the urinary tract: the elongated swarmer cell is rarely observed in ascending urinary tract infection. Infect Immun. 2003;71:3607–13.CrossRefPubMedPubMedCentral
16.
Mobley HL, Belas R. Swarming and pathogenicity of Proteus Mirabilis in the urinary tract. Trends Microbiol. 1995;3:280–4.CrossRefPubMed
17.
Mathur S, Sabbuba NA, Suller MTE, Stickler DJ, Feneley RCL. Genotyping of urinary and fecal Proteus Mirabilis isolates from individuals with long-term urinary catheters. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2005;24:643–4.CrossRef
18.
19.
20.
Jacobsen SM, Stickler DJ, Mobley HLT, Shirtliff ME. Complicated catheter-associated urinary tract infections due to Escherichia Coli and Proteus Mirabilis. Clin Microbiol Rev. 2008;21:26–59.CrossRefPubMedPubMedCentral
21.
Rózalski A, Sidorczyk Z, Kotełko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev MMBR. 1997;61:65–89.PubMed
22.
23.
24.
Pearson MM, Sebaihia M, Churcher C, Quail MA, Seshasayee AS, Luscombe NM, et al. Complete genome sequence of uropathogenic Proteus Mirabilis, a master of both adherence and motility. J Bacteriol. 2008;190:4027–37.CrossRefPubMedPubMedCentral
25.
Habibi M, Asadi Karam MR, Bouzari S. In silico design of fusion protein of FimH from uropathogenic Escherichia Coli and MrpH from Proteus Mirabilis against urinary tract infections. Adv. Biomed Res. 2015;4:217.PubMedPubMedCentral
26.
Baldo C, Rocha SPD. Virulence factors of Uropathogenic Proteus Mirabilis - a mini review. Int. J. Technol. Enhanc. Emerg. Eng. Res. 2014;3:24–7.
27.
Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol. 2010;13:558–64.CrossRefPubMed
28.
29.
Horner CS, Abberley N, Denton M, Wilcox MH. Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010-2012. Epidemiol Infect. 2014;142:399–403.CrossRefPubMed
30.
Miró E, Agüero J, Larrosa MN, Fernández A, Conejo MC, Bou G, et al. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2013;32:253–9.CrossRef
31.
Sheng W-H, Badal RE, Hsueh P-R, Program SMART. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother. 2013;57:2981–8.CrossRefPubMedPubMedCentral
32.
Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther. 2013;35:872–7.CrossRefPubMed
33.
Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, et al. Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011. J Inf Secur. 2014;68:71–6.
34.
Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Walkty AJ, Hoban DJ, et al. Vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother. 2013;57:5600–11.CrossRefPubMedPubMedCentral
35.
Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014;78:443–8.CrossRefPubMed
36.
Chen L, Al Laham N, Chavda KD, Mediavilla JR, Jacobs MR, Bonomo RA, et al. First report of an OXA-48-producing multidrug-resistant Proteus Mirabilis strain from Gaza, Palestine. Antimicrob Agents Chemother. 2015;59:4305–7.CrossRefPubMedPubMedCentral
37.
Latif U, Al-Rubeaan K, Saeb ATM. A review on antimicrobial chitosan-silver nanocomposites: a roadmap toward pathogen targeted synthesis. Int J Polym Mater Polym Biomater. 2015;64:448–58.CrossRef
38.
Matuschek E, Brown DFJ, Kahlmeter G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect Dis. 2014;20:O255–66.
39.
Holla G, Yeluri R, Munshi AK. Evaluation of minimum inhibitory and minimum bactericidal concentration of nano-silver base inorganic anti-microbial agent (Novaron(®)) against streptococcus mutans. Contemp. Clin Dent. 2012;3:288–93.CrossRefPubMedPubMedCentral
40.
Yassien M, Khardori N. Interaction between biofilms formed by Staphylococcus Epidermidis and quinolones. Diagn Microbiol Infect Dis. 2001;40:79–89.CrossRefPubMed
41.
42.
Darling ACE, Mau B, Blattner FR, Perna NT. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res. 2004;14:1394–403.CrossRefPubMedPubMedCentral
43.
44.
Wattam AR, Abraham D, Dalay O, Disz TL, Driscoll T, Gabbard JL, et al. PATRIC, the bacterial bioinformatics database and analysis resource. Nucleic Acids Res. 2014;42:D581–91.CrossRefPubMed
45.
Cosentino S, Voldby Larsen M, Møller Aarestrup F, Lund O. PathogenFinder--distinguishing friend from foe using bacterial whole genome sequence data. PLoS One. 2013;8:e77302.CrossRefPubMedPubMedCentral
46.
47.
48.
McArthur AG, Wright GD. Bioinformatics of antimicrobial resistance in the age of molecular epidemiology. Curr Opin Microbiol. 2015;27:45–50.CrossRefPubMed
49.
McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The comprehensive antibiotic resistance database. Antimicrob Agents Chemother. 2013;57:3348–57.CrossRefPubMedPubMedCentral
50.
Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67:2640–4.CrossRefPubMedPubMedCentral
51.
Pal C, Bengtsson-Palme J, Rensing C, Kristiansson E, Larsson DGJ. BacMet: antibacterial biocide and metal resistance genes database. Nucleic Acids Res. 2014;42:D737–43.CrossRefPubMed
52.
53.
Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2012;18:268–81.
54.
55.
Tang Z, Liu S, Dong S, Wang E. Electrochemical synthesis of ag nanoparticles on functional carbon surfaces. J Electroanal Chem. 502:146–51.
56.
Park H-J, Kim JY, Kim J, Lee J-H, Hahn J-S, MB G, et al. Silver-ion-mediated reactive oxygen species generation affecting bactericidal activity. Water Res. 2009;43:1027–32.CrossRefPubMed
57.
58.
Vaaje-Kolstad G, Horn SJ, van Aalten DMF, Synstad B, Eijsink VGH. The non-catalytic chitin-binding protein CBP21 from Serratia Marcescens is essential for chitin degradation. J Biol Chem. 2005;280:28492–7.CrossRefPubMed
59.
Svitil AL, Chadhain S, Moore JA, Kirchman DL. Chitin degradation proteins produced by the marine bacterium Vibrio Harveyi growing on different forms of chitin. Appl Environ Microbiol. 1997;63:408–13.PubMedPubMedCentral
60.
Wieczorek AS, Hetz SA, Kolb S. Microbial responses to chitin and chitosan in oxic and anoxic agricultural soil slurries. Biogeosciences. 2014;11:3339–52.CrossRef
61.
Gupta V, Prasanna R, Natarajan C, Srivastava AK, Sharma J. Identification, characterization, and regulation of a novel antifungal chitosanase gene (cho) in anabaena spp. Appl Environ Microbiol. 2010;76:2769–77.CrossRefPubMedPubMedCentral
62.
Gupta V, Prasanna R, Srivastava AK, Sharma J. Purification and characterization of a novel antifungal endo-type chitosanase from anabaena fertilissima. Ann Microbiol. 2011;62:1089–98.CrossRef
63.
Cutting K, White R, Edmonds M. The safety and efficacy of dressings with silver - addressing clinical concerns. Int Wound J. 2007;4:177–84.CrossRefPubMed
64.
65.
Stephens S, Clark R, Del Bono M, Snyder R. Designing in vitro, in vivo and clinical evaluations to meet the needs of the patient and clinician: dressing wound adherence. Geneva; 2010.
66.
Thomas S. Alginate dressings in surgery and wound management--part 1. J Wound Care. 2000;9:56–60.CrossRefPubMed
67.
Thomas S. Alginate dressings in surgery and wound management: part 2. J Wound Care. 2000;9:115–9.CrossRefPubMed
68.
Thomas S. Alginate dressings in surgery and wound management: part 3. J Wound Care. 2000;9:163–6.CrossRefPubMed
69.
70.
Haycocks S, Chadwick P. Using an activated charcoal dressing with silver for malodour, infection and overgranulation in diabetic foot ulcers importance of appropriate dressing selection for diabetic foot ulcers. Diabet Foot J. 2014;17:74–7.
71.
Allison C, Lai HC, Hughes C. Co-ordinate expression of virulence genes during swarm-cell differentiation and population migration of Proteus Mirabilis. Mol Microbiol. 1992;6:1583–91.CrossRefPubMed
72.
73.
Lai S, Tremblay J, Déziel E. Swarming motility: a multicellular behaviour conferring antimicrobial resistance. Environ Microbiol. 2009;11:126–36.CrossRefPubMed
74.
75.
76.
Wu YL, Liu KS, Yin XT, Fei RM. GlpC gene is responsible for biofilm formation and defense against phagocytes and imparts tolerance to pH and organic solvents in Proteus vulgaris. Genet Mol Res GMR. 2015;14:10619–29.CrossRefPubMed
77.
Jiang S-S, Liu M-C, Teng L-J, Wang W-B, Hsueh P-R, Liaw S-J. Proteus Mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion. Antimicrob Agents Chemother. 2010;54:1564–71.CrossRefPubMedPubMedCentral
78.
Chien C-C, Lin B-C, Biofilm WC-H. Formation and heavy metal resistance by an environmental pseudomonas sp. Biochem Eng J. 2013;78:132–7.CrossRef
79.
Nocelli N, Bogino PC, Banchio E, Giordano W. Roles of extracellular polysaccharides and biofilm formation in heavy metal resistance of rhizobia. Materials. 2016;9:418.CrossRefPubMedCentral
80.
Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–32.CrossRefPubMed
81.
Li XZ, Nikaido H, Williams KE. Silver-resistant mutants of Escherichia Coli display active efflux of ag+ and are deficient in porins. J Bacteriol. 1997;179:6127–32.CrossRefPubMedPubMedCentral
82.
Lok C-N, Ho C-M, Chen R, Tam PK-H, Chiu J-F, Che C-M. Proteomic identification of the Cus system as a major determinant of constitutive Escherichia Coli Silver resistance of chromosomal origin. J Proteome Res. 2008;7:2351–6.CrossRefPubMed
83.
Randall CP, Gupta A, Jackson N, Busse D, O’Neill AJ. Silver resistance in gram-negative bacteria: a dissection of endogenous and exogenous mechanisms. J Antimicrob Chemother. 2015;70:1037–46.PubMedPubMedCentral
84.
Zhang W, Yin K, Li B, Chen LA. Glutathione S-transferase from Proteus Mirabilis involved in heavy metal resistance and its potential application in removal of Hg2+. J Hazard Mater. 2013;261:646–52.CrossRefPubMed
85.
Nair PMG, Choi J. Identification, characterization and expression profiles of Chironomus Riparius glutathione S-transferase (GST) genes in response to cadmium and silver nanoparticles exposure. Aquat Toxicol Amst Neth. 2011;101:550–60.CrossRef
86.
Toptchieva A, Sisson G, Bryden LJ, Taylor DE, Hoffman PS. An inducible tellurite-resistance operon in Proteus Mirabilis. Microbiol Read Engl. 2003;149:1285–95.CrossRef
87.
Qin J, Lehr CR, Yuan C, Le XC, McDermott TR, Rosen BP. Biotransformation of arsenic by a Yellowstone thermoacidophilic eukaryotic alga. Proc Natl Acad Sci U S A. 2009;106:5213–7.CrossRefPubMedPubMedCentral
88.
Qin J, Rosen BP, Zhang Y, Wang G, Franke S, Rensing C. Arsenic detoxification and evolution of trimethylarsine gas by a microbial arsenite S-adenosylmethionine methyltransferase. Proc Natl Acad Sci U S A. 2006;103:2075–80.CrossRefPubMedPubMedCentral
89.
Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, et al. CDD: NCBI’s conserved domain database. Nucleic Acids Res. 2015;43:D222–6.CrossRefPubMed
90.
Srinivasan VB, Vaidyanathan V, Mondal A, Rajamohan G. Role of the two component signal transduction system CpxAR in conferring cefepime and chloramphenicol resistance in Klebsiella Pneumoniae NTUH-K2044. PLoS One. 2012;7:e33777.CrossRefPubMedPubMedCentral
91.
Nawaz M, Sung K, Kweon O, Khan S, Nawaz S, Steele R. Characterisation of novel mutations involved in quinolone resistance in Escherichia Coli isolated from imported shrimp. Int J Antimicrob Agents. 2015;45:471–6.CrossRefPubMed
92.
Kubanov A, Vorobyev D, Chestkov A, Leinsoo A, Shaskolskiy B, Dementieva E, et al. Molecular epidemiology of drug-resistant Neisseria gonorrhoeae in Russia (current status, 2015). BMC Infect Dis. 2016;16:389.CrossRefPubMedPubMedCentral
93.
Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia Coli rpoB gene that lead to rifampicin resistance. J Mol Biol. 1988;202:45–58.CrossRefPubMed
94.
Zhao J, Aoki T. Cloning and nucleotide sequence analysis of a chloramphenicol acetyltransferase gene from vibrio anguillarum. Microbiol Immunol. 1992;36:695–705.CrossRefPubMed
95.
Bay DC, Rommens KL, Turner RJ. Small multidrug resistance proteins: a multidrug transporter family that continues to grow. Biochim Biophys Acta. 2008;1778:1814–38.CrossRefPubMed
96.
Lee J-Y, Ko KS. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas Aeruginosa clinical isolates. Diagn Microbiol Infect Dis. 2014;78:271–6.CrossRefPubMed
97.
Franke S, Grass G, Rensing C, Nies DH. Molecular analysis of the copper-transporting efflux system CusCFBA of Escherichia Coli. J Bacteriol. 2003;185:3804–12.CrossRefPubMedPubMedCentral
98.
Nishino K, Nikaido E, Yamaguchi A. Regulation of multidrug efflux systems involved in multidrug and metal resistance of salmonella enterica serovar typhimurium. J Bacteriol. 2007;189:9066–75.CrossRefPubMedPubMedCentral
99.
Outten FW, Huffman DL, Hale JA, O’Halloran TV. The independent cue and cus systems confer copper tolerance during aerobic and anaerobic growth in Escherichia Coli. J Biol Chem. 2001;276:30670–7.CrossRefPubMed
100.
Metadata
Title
Genome sequencing and analysis of the first spontaneous Nanosilver resistant bacterium Proteus mirabilis strain SCDR1
Authors
Amr T. M. Saeb
Khalid A. Al-Rubeaan
Mohamed Abouelhoda
Manojkumar Selvaraju
Hamsa T. Tayeb
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2017
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-017-0277-x

Other articles of this Issue 1/2017

Antimicrobial Resistance & Infection Control 1/2017 Go to the issue

Research

Risk factors for Clostridium difficile infection in surgical patients hospitalized in a tertiary hospital in Belgrade, Serbia: a case–control study

Research

Fecal carriage of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in Egyptian patients with community-onset gastrointestinal complaints: a hospital -based cross-sectional study

Research

Prevalence and pattern of antibiotic resistance of Staphylococcus aureus isolated from door handles and other points of contact in public hospitals in Ghana

Letter to the Editor

Screening and contact precautions – A survey on infection control measures for multidrug-resistant bacteria in German university hospitals

Review

How externalities impact an evaluation of strategies to prevent antimicrobial resistance in health care organizations

Research

Implementation of central line-associated bloodstream infection prevention bundles in a surgical intensive care unit using peer tutoring

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits